Poor Yield of Routine Transthyretin Screening in Patients with Idiopathic Neuropathy
Open Access
- 4 June 2020
- journal article
- research article
- Published by Cambridge University Press (CUP) in Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
- Vol. 47 (6) , 816-819
Abstract
Background and objectives: Transthyretin familial amyloid polyneuropathy (TTR-FAP) is caused by a mutation in the transthyretin (TTR) gene. Although classically described as rapidly progressive and life-threatening, recent studies on TTR-FAP show significant genetic and phenotypic heterogeneity depending on geographic localization. In light of new therapeutic advances and their implication for patient management, the aim of our study was to determine the prevalence of TTR-FAP within patients with idiopathic neuropathy in a North American population.Methods: We sequenced the TTR gene in a cohort of patients with idiopathic neuropathy. Genetic screening was performed in 110 patients from two neuromuscular clinics in Montreal, Canada.Results: No variants of unknown significance or pathogenic mutations were detected in the TTR gene.Conclusion: Our study confirms that TTR-FAP is a rare entity in our patient population, and that diagnostic yield of screening all patients with idiopathic neuropathy is very low.Keywords
This publication has 20 references indexed in Scilit:
- “Red‐flag” symptom clusters in transthyretin familial amyloid polyneuropathyJournal of the Peripheral Nervous System, 2016
- A Review of Tafamidis for the Treatment of Transthyretin-Related AmyloidosisNeurology and Therapy, 2015
- Liver transplantation in transthyretin amyloidosis: Issues and challengesLiver Transplantation, 2015
- Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosisAmyloid, 2014
- Guideline of transthyretin-related hereditary amyloidosis for cliniciansOrphanet Journal of Rare Diseases, 2013
- THAOS – The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosisCurrent Medical Research and Opinion, 2012
- Familial amyloid polyneuropathyThe Lancet Neurology, 2011
- Electrophysiological features of late-onset transthyretin Met30 familial amyloid polyneuropathy unrelated to endemic fociJournal of Neurology, 2008
- Is familial amyloid polyneuropathy rare?Neurology, 2007
- Transthyretin amyloidosis presenting with multifocal demyelinating mononeuropathiesMuscle & Nerve, 2004